Dr. Cassandra Pierre is an Assistant Professor at the Boston University School of Medicine; she serves as the Medical Director of Public Health Programs and the acting Hospital Epidemiologist at Boston Medical Center; and as the Chair of the Diversity and Inclusion Council for the Boston University Medical Group. Her focus is on population and public health in communities struggling with racial, economic and social marginalization. Dr. Pierre's research is focused on infection prevention in vulnerable populations. Her clinical interests include HIV management in special subpopulations (including immigrants of color and pregnant women). During the COVID-19 pandemic, she has led Boston Medical Center's multidisciplinary Infection Prevention and PPE response, designed ambulatory and operative re-opening protocols and advised Occupational Health and department leadership on COVID-19 prevention in healthcare workers. Dr. Pierre has also collaborated with local community organizations to develop and implement strategies to reduce COVID-19 infection in communities of color).
Dr. Cassandra Pierre
Dr. Mark Dybul
The Honorable Mark Dybul, MD, is the Co-Director of the Center for Global Health Practice and Impact, and Professor in the Department of Medicine at Georgetown University Medical Center. He is also a Chair and Fellow with the Joep Lange Institute. A well-recognized global health expert and humanitarian, Dr. Dybul served as Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, and as the U.S. Global AIDS Coordinator, overseeing the implementation of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Dr. Dybul served as a HIV research fellow at the National Institute for Allergy and Infectious Diseases (NIAID) under director Dr. Anthony Fauci in the late 1990s. He conducted basic and clinical HIV research at NIAID, and eventually conducted the first randomized, controlled trial with combination antiretroviral therapy with HIV patients in Africa. He went on to lead President George W. Bush’s International Prevention of Mother and Child HIV initiative for the Department of Health and Human Services (HHS), and in 2006 was named U.S. Global AIDS Coordinator. As U.S. Global AIDS Coordinator, he led the implementation of PEPFAR, a health initiative Dr. Dybul helped create. He later became the inaugural Global Health Fellow of the George W. Bush Institute.
Charlie helped found Adjuvant Capital while at the Global Health Investment Fund (GHIF) where he focused on investments in medical device companies, including the fund’s investments in IanTech (acquired by Zeiss) and Alydia Health. Before joining GHIF, Charlie was with Artemis Capital Partners, where he made private equity investments in industrial technology companies with a focus on the scientific instrumentation and advanced materials sectors. Previously, he lived in Haiti and worked at the country’s largest microfinance bank, Sevis Finansye Fonkoze, where he led financial and operational analysis efforts. Charlie remains active in Haiti and serves on the boards of Sevis Finansye Fonkoze and Fonkoze USA. He is a graduate of the Virginia Polytechnic Institute.
Ms. Arthur is responsible for working with member companies in vaccines, antimicrobial resistance, molecular diagnostics, and biodefense on policy, legislative and regulatory issues. Ms. Arthur joined BIO in July 2009 as the Director of Healthcare Regulatory Affairs. Prior to joining BIO, she worked in numerous marketing and sales positions for Merck & Co Inc in their Vaccine Division. Over her 16-year career in vaccines, Ms. Arthur launched several exciting new vaccines in the United States and internationally, including the first HPV vaccine, GARDASIL. During her years in Marketing, she worked closely with clinical and academic thought leaders in infectious diseases, oncology, and public health. In addition, Ms. Arthur also led a large vaccine sales organization of over 75 representatives and managers covering 14 states. Before graduate school, Ms. Arthur worked as a research assistant for two economists at the Brookings Institution in Washington, DC. There she conducted economic analyses related to savings and investment policies for the OECD countries. Ms. Arthur received her B.A. in 1987 in Economics and International Politics from Goucher College and her M.B.A. in 1991 from the Wharton School of Business at the University of Pennsylvania.
Kimberly Mutcherson is Co-Dean and Professor of Law at Rutgers Law School in Camden. Her scholarly work is at the intersection of family law, health law, and bioethics. She writes on issues related to reproductive justice, with a focus on assisted reproduction, abortion, and maternal-fetal decision-making. Professor Mutcherson teaches Family Law, Torts, South African Constitutional Law, and Bioethics, Babies, & Babymaking. She has served as a Senior Fellow/Sabbatical Visitor at the Center for Gender and Sexuality Law at Columbia Law School, a Visiting Scholar at the Center for Bioethics at the University of Pennsylvania, and as a fellow at the Institute for Research on Women at Rutgers University. She won a Center for Reproductive Rights Innovation in Scholarship Award in 2013 and a Chancellor’s Teaching Excellence Award in 2011.She received her B.A. in history from the University of Pennsylvania and her J.D. from Columbia Law School where she was a Stone Scholar. At Columbia, she received the Samuel I. Rosenman Prize for excellence in public law courses and outstanding qualities of citizenship and leadership in the law school. She also received the Kirkland and Ellis Fellowship for post- graduate public interest work. Prior to joining the faculty at Rutgers School of Law in 2002, Professor Mutcherson was an Acting Assistant Professor of Lawyering at the New York University School of Law, a consulting attorney at the Center for Reproductive Law and Policy (now the Center for Reproductive Rights), and a Staff Attorney at the HIV Law Project.
Dr. Weissman's laboratory focuses on the study of RNA and innate immune system biology and the application of these findings to vaccine research and gene therapy. There are three main projects in his laboratory. The first project began through the use of mRNA encoding antigen as a delivery system to load dendritic cells to promote broad immune responses as part of a vaccine. This project has expanded to include basic studies of RNA immunogenicity and translation and the development of applications for gene therapy. The second project develops new HIV envelope immunogens that can induce broad responses and cross-reactive neutralizing antibodies. The third project continues previous studies that identified a protein found on DC, macrophages, and epithelial cells that binds HIV envelope with high affinity. The main focus of this project is testing whether these and related molecules function in vivo to promote HIV genital tract infection.
Dr. Drew Weissman
Ruth Atherton is primarily responsible for legal services to the foundation’s Global Health division and supporting the Bill & Melinda Gates Medical Research Institute. In this role, she provides legal, compliance, policy, and strategic advice on a broad portfolio of grants, contracts, and investments. She is the executive sponsor of the foundation’s Global Access Team, which leads the development and implementation of the foundation’s intellectual property strategy and creates affordable access to the products and developments funded by the foundation to benefit the world’s populations who are most in need. Prior to joining the foundation in 2012, Ruth was senior corporate counsel at Sanofi, supporting Industrial Affairs, and senior Intellectual Property (IP) Counsel at Genzyme Corporation supporting Global Manufacturing and Operations. Ruth was an IP litigation attorney at Fitzpatrick, Cella, Harper & Scinto in NYC, where she supported biotech and pharmaceutical litigation. Ruth holds a Ph.D. in Cell and Molecular Biology from Cornell University and a J.D. from Fordham School of Law. She is admitted to the bar in Washington, New York, Massachusetts, the District of Columbia, and the U.S. Court of Appeals for the Federal Circuit. She is a registered patent attorney and a member of the International Law Association’s Global Health Law Committee.